Preparation export spring has not yet arrived in the transformation of API enterprises can not wait

June 20-22, sponsored by BOT Exhibition Consulting Co., Ltd., China Pharmaceutical Health Products Import and Export Chamber of Commerce, Shanghai Bohua International Exhibition Co., Ltd. co-sponsored the 17th World Pharmaceutical Raw Materials China Exhibition, the 12th World Pharmaceutical Machinery, Packaging Equipment and Materials China Exhibition, the 5th World Pharmaceutical Contract Custom Service China Exhibition and the 5th World Pharmaceutical Contract Custom Service China Exhibition, 2017 World Natural Extracts Exhibition held in Shanghai.
reporters understand that the exhibition expanded the exhibition area, from more than 120 countries and regions, 2800 enterprises exhibiting, more than 50,000 professional buyers to the meeting. The exhibition also launched a new brand zone - pharmaceutical preparations and technology zone and the new China Pharmaceutical Week activities: like the World Pharmaceutical Raw Materials Europe Exhibition, the establishment of pharmaceutical preparations and technology zones can effectively promote the rapid development of China's pharmaceutical industry. It is predicted that the preparation zone plate will become the fastest growing plate in China in the next few years.
At the opening ceremony of the exhibition, Zhou Hui, President of the China Medical and Health Products Import and Export Chamber of Commerce (the "Medical Insurance Chamber of Commerce"), stressed: "The pharmaceutical industry is one of the most promising industries in the world, and has maintained a relatively stable growth trend for many years." Today, the global pharmaceutical industry has undergone profound changes, and its supply chain and value chain layout are being reshaped. As a global pharmaceutical power, China has achieved remarkable results in the field of chemical raw materials and natural extracts, and its international influence is increasing day by day. Xu Ming, vice president of ICH to accelerate the process of internationalization
said: "This year's participation is significantly higher than last year's, foreign merchants significantly more than last year, the exhibition area has also set a new record high." The exhibition is still the window and barometer of the industry. Judging from the overall situation, China's position as a major API country has not changed and still occupies an important position in the layout of the global industrial chain. On the other hand, the export of preparations is growing very fast, and the export of preparations is expected to reach more than US$3 billion in 2017, which will maintain a 10% growth rate. On
in the export of preparations, Xu Ming said: "The spring of the export of preparations is far from coming." Reporters
found that ICH has become the most concerned topic during the exhibition. With China's announcement of conditional accession to ICH, the process of internationalization of Chinese preparations is expected to accelerate significantly. Xu Ming introduced: "ICH will change the trend of China's internationalization, in the space and time of the two dimensions, China's mainland are facing competition from abroad, China's new drug research and development has needed to be reported between China and the United States." Domestic and foreign registration, mutual recognition of data, sharing of regulatory verification results, enterprises need to achieve the unity of space and time, on the other hand, foreign pharmaceutical companies are expected to develop innovative drugs faster in the domestic market, Chinese enterprises can also through overseas mergers and acquisitions, access to marketing networks and resources, overseas products as soon as possible to domestic sales. This shows that the future pharmaceutical companies should dare to try innovation, not only commercial innovation, but also strategic and management innovation. Theenterprises is still slow
from the situation in the first half of 2017, China's API export situation is still good. However, there are serious hidden worries behind it, and the volume of price increases and falls is still the main theme. Under the background of going to capacity, China's overcapacity of chinese raw materials is still serious.Xu Ming stressed:
IND pharmaceutical enterprises are urgently transformed, China's API enterprises should not only eliminate backward production capacity, but also appropriately transfer some API industries abroad, accelerate the pace of industrial transfer." "In Indonesia, for example, where the pharmaceutical industry is growing so fast that many multinational pharmaceutical companies have set up factories there, the country also imports large quantities of raw materials from China. "We can consider capacity transfer in these high-growth markets, not necessarily to produce preparations and biologics, and some API can also land, " Xu suggests. Yan Bing, deputy general manager of
National Pharmaceuticals International, said: "To the investment of Chinese medicine in Vietnam, for example, our feeling is that only product trade is easy to arouse the disgust of the local people, feel that Chinese enterprises are to grab jobs, we through local investment in factories, to solve local employment, so that we have been welcomed by the local people, so as to better develop the local market." From our experience, investing is a better way to integrate into the local market. The market
different countries varies greatly from country to country, which is also the biggest obstacle many Chinese enterprises encounter in the process of internationalization. Xu Ming pointed out: "Chinese enterprises go out, we must go into the countryside with the common customs, in the domestic selling good products, not necessarily selling well abroad; Therefore, different access strategies and channels should be adopted according to different countries and regions. In
first half of 2016-2017, China's imports of preparations were still larger than exports. Thus, as the world's second largest pharmaceutical market, China's pharmaceutical demand is still extremely strong.
, China cannot give up on the API industry, " Mr Xu stressed. One of the great advantages of Chinese enterprises' preparation exports is that we have our own high-quality, cheap raw materials. Therefore, the API industry is still fundamental, API enterprises need to transform, preparations and specialty API is the direction of development, due to the large amount of API, the transformation process will still be more difficult. (Medical Economics)